金陵藥業(000919.SZ):全資子公司以1.16億元競得合肥市蜀山區一社會福利用地
格隆匯2月17日丨金陵藥業(000919.SZ)公佈,2022年2月16日,公司全資子公司合肥金陵天頤智慧養老服務有限公司(以下簡稱“金陵天頤”)在合肥市土地交易市場舉辦的國有建設用地使用權拍賣轉掛牌出讓活動中,以人民幣371萬元/畝的成交價格公開競得合肥市蜀山區SS202201號地塊的國有土地使用權。宗地面積為31.2畝(具體面積以實地測繪為準),並與合肥市自然資源和規劃局簽訂了《合肥市國有建設用地使用權出讓成交確認書》。地塊位置:蜀山區史河路以南、青陽路以東。土地用途:社會福利用地。成交價:人民幣1.16億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.